OVdialogue – consider joining our team in the role of Community Champion. Over a few hours each week, you would be part of a team that helps connect people, support conversations and are thought leaders for OVdialogue. This is your opportunity to give back to those who have/continue to support you through the tough times, share your unique experiences, and help celebrate successes. For more details of what this entails, please reach out to @Mfallis (mfallis@ovariancanada.org).
• A personalized experience, just for you: your member homepage displays the content you engage with most, including a resource library where you can engage in discussions directly related to the content.
• Have conversations in real time: You can respond to notifications and personal messages from people in your community directly from your email inbox; plus it’s easier than ever to return to the platform.
• Stay up to date on the latest events: upcoming activities will be listed in an events calendar right here in the platform
During this time of transition, private messaging within the platform will be unavailable beginning January 22, and posting will be unavailable beginning January 27.
We look forward to seeing you in the refreshed platform!
Patient input needed by December 5th to help bring ELAHERE to Canada
If you or someone you know has taken the drug ELAHERE (mirvetuximab-soravtansine) and are interested in taking part in a 20-minute interview with OCC staff so that your experience with this treatment can be considered in the drug approval process in Canada, please contact Alexandria Tadman, atadman@ovariancanada.org by December 5, 2024.
Thanks!
Comments
-
My mom fought hard against this disease and made every effort to access promising treatments. She even traveled to the U.S. to consult with a doctor, but unfortunately, it didn’t lead to the results we hoped for. Elahere has a 35% response rate for platinum-resistant patients—significantly higher than the 10% response rate of most third-tier drugs currently available.
This difference in efficacy is staggering and could mean the world to so many families battling ovarian cancer. Patients shouldn’t have to face insurmountable barriers to access potentially life-saving treatments. I sincerely hope this drug is approved soon so others won’t have to go through the same struggles my mom faced.
Thank you for considering this important issue.
0 -
@mymomisawarrior thank you for sharing your comments here. If you'd be willing to have a conversation about your mom's experience, please reach out to Alexandria (atadman@ovariancanada.org), she would appreciate your input.
1 -
@mfallis she never took the drug as it wasn’t available to her. I can certainly speak on the struggle to access it.
1
